Drug Trial Radar · NCT07673107
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Jun 23, 2026
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET. AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada. Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks. The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.
Conditions
- Upper Limb Essential Tremor
Interventions
AGN-151607-DPDrug
Intramuscular Injection
Placebo for AGN-151607-DPDrug
Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)Time frame: 72 weeks
- Number of Participants with Adverse Events (AEs)Time frame: 72 weeks
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
The Neurology Center of Southern California - Carlsbad /ID# 278194
Carlsbad, California · Recruiting
Neuro Pain Research Center /ID# 277899
Fresno, California · Recruiting
Neurology Center Of North Orange County /ID# 278490
Fullerton, California · Recruiting
New England Institute for Clinical Research /ID# 277315
Stamford, Connecticut · Recruiting
Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
Boca Raton, Florida · Recruiting
Charter Research - Winter Park /ID# 277875
Orlando, Florida · Recruiting
Emerald Coast Neurology /ID# 277898
Pensacola, Florida · Recruiting
Kansas Institute of Research /ID# 277068
Overland Park, Kansas · Recruiting
Dent Neurologic Institute - Amherst /ID# 277242
Amherst, New York · Recruiting
True North Neurology /ID# 278118
Commack, New York · Recruiting
Neurology - Triad /ID# 277088
Winston-Salem, North Carolina · Recruiting
Mount Carmel Health System /ID# 278234
New Albany, Ohio · Recruiting
Veracity Neuroscience /ID# 277081
Memphis, Tennessee · Recruiting
Texas Neurology /ID# 277067
Dallas, Texas · Recruiting
Lone Star Neurology /ID# 278266
Frisco, Texas · Recruiting
Houston Methodist Hospital /ID# 277326
Houston, Texas · Recruiting
University of Virginia /ID# 278191
Charlottesville, Virginia · Recruiting
Inland Northwest Research /ID# 277077
Spokane, Washington · Recruiting
Center For Neurological Disorders /ID# 277048
Greenfield, Wisconsin · Recruiting
True North Clinical Research /ID# 277130
Halifax, Nova Scotia, Canada · Recruiting
Centre de Recherche St-Louis /ID# 277106
Lévis, Quebec, Canada · Recruiting
Genge Partners /ID# 277096
Pointe-Claire, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.